
NICE Not Alone in Pushback on Cancer Drug Prices
The Colombian government is forcing pharmaceutical giant Novartis to lower prices of its leukemia medicine, imatinib (Gleevec).
The Colombian government is forcing pharmaceutical giant Novartis to lower prices of its leukemia medicine, imatinib (Gleevec).
According to
The basic compound patent on imatinib mesylate
Interestingly, payers would still include the generic imatinib in the specialty tier (threshold is $600 for a 1-month supply), as Michael Kolodziej, MD, national medical director of Aetna,
Colombia’s dispute with Novartis could set a precedent for middle income countries as they struggle to meet the rising prices of potentially curative treatments in cancer. The dispute, according to the report, could have much broader implications on trade negotiations between the United States and Colombia.
Novartis, meanwhile, said that disagreements stemmed from the fact that price control strategies are already in place in Colombia, in addition to generic competition.
Colombia has a government-funded health system, and the ministry of health has estimated that funding the $15,000 annual course of Gleevec would cost the government $15 million per year.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.